67376-94-7

Basic information

• Product Name: N-CYCLOPROPYL-METHYLAMINE HCL
• Synonyms: N-CYCLOPROPYL-METHYLAMINE HCL;N-Methylcyclopropanamine Hydrochloride;N-Cyclopropyl-methylamine hydrochloride;N-MethylcyclopropanaMine, HCl;N-Cyclopropyl-methylamine x HCl;Cyclopropanamine, N-methyl-, hydrochloride
• CAS NO: 67376-94-7
• Molecular Formula: C4H10ClN
• Molecular Weight: 107.58
• Mol File: 67376-94-7.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 120.5 °C at 760 mmHg
• Flash Point: 26.7 °C
• Appearance: /
• Vapor Pressure: 13.9mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: N-CYCLOPROPYL-METHYLAMINE HCL(CAS DataBase Reference)
• NIST Chemistry Reference: N-CYCLOPROPYL-METHYLAMINE HCL(67376-94-7)
• EPA Substance Registry System: N-CYCLOPROPYL-METHYLAMINE HCL(67376-94-7)

Safety Data

• Hazardous Substances Data: 67376-94-7(Hazardous Substances Data)

Usage

Uses

N-?Methylcyclopropanami?ne Hydrochloride can be used as reactant/reagent in preparation of substituted benzazinones as antibacterial compounds.

InChI:InChI=1/C4H9N.ClH/c1-5-4-2-3-4;/h4-5H,2-3H2,1H3;1H

Upstream product

• 897932-58-0 tert-butyl N-(cyclopropylmethyl)carbamate 
• 91245-57-7 N-benzyl-N-cyclopropyl-N-methylamine 
• 58644-54-5 N-cyclopropylformamide 

Downstream Products

• 1177423-59-4 (4-(cyclopropyl(methyl)carbamoyl)phenyl)boronic acid 

Relevant articles and documents

N-(1H-IMIDAZOL-2-YL)BENZAMIDE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT

N-(1H-imidazol-2-yl)benzamide compound of formula (I), or a pharmaceutically acceptable salt, a prodrug, a solvate, or a stereoisomer thereof which is a novel compound exhibiting excellent inhibitory activity against IRAK-4, can be used without side effects for efficient prevention and treatment of diseases mediated by IRAK-4 receptors, particularly autoimmune diseases or lymphomas.

Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor

Currently, a lack of sufficient tools has limited the understanding of the relationship between neuropsychiatric disorders and the nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor. Herein, we describe the discovery and development of an antagonist NOP receptor occupancy (RO) tracer and a novel positron emission tomography (PET) radioligand suitable to probe the NOP receptor in human clinical studies. A thorough structure-activity relationship (SAR) around the high-affinity 3-(2′-fluoro-4′,5′- dihydrospiro[piperidine-4,7′-thieno[2,3-c]pyran]-1-yl)-2-(2-halobenzyl) -N-alkylpropanamide scaffold identified a series of subnanomolar, highly selective NOP antagonists. Subsequently, these unlabeled NOP ligands were evaluated in vivo by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in rat to determine brain uptake, kinetics and specific binding. (S)-27 was identified as a suitable unlabeled preclinical RO tracer to accurately quantify NOP receptor engagement in rat brain. Three compounds were selected for evaluation in nonhuman primates as PET tracers: (-)-26, (-)-30, and (-)-33. Carbon-11 labeling of (+)-31 yielded [11C]-(S)-30, which exhibited minimal generation of central nervous system (CNS) penetrant radiometabolites, improved brain uptake, and was an excellent PET radioligand in both rat and monkey. Currently [11C]-(S)-30 is being evaluated as a PET radiotracer for the NOP receptor in human subjects.

MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 6: Exploration of aromatic substituents

A series of 4-oxo-4H-pyrido[1,2-a]pyrimidine derivatives, derivatized at the 2-position with aromatic substituents, were synthesized by the Suzuki cross-coupling method and evaluated for their ability to potentiate the activity of the fluoroquinolone levo